Celgene Corp Combination Therapy Patent US12605372B2 Granted
Summary
The USPTO granted Patent US12605372B2 to Celgene Corporation on April 21, 2026. The patent covers methods of treating cancers by administering Compound A in combination with daratumumab, or Compound A with daratumumab and dexamethasone. The patent contains 19 claims and derives from Application No. 17983762, filed November 9, 2022.
What changed
USPTO granted Celgene Corporation Patent US12605372B2, a combination therapy patent covering methods of treating cancers using Compound A with daratumumab, with or without dexamethasone. The patent contains 19 claims and is classified under CPC codes A61K 31/4035, A61K 31/45, A61K 47/6849, and A61P 35/00.
Pharmaceutical companies developing or commercialising combination cancer therapies should review this patent to assess freedom-to-operate implications, particularly for therapies combining IMiD compounds with daratumumab. The patent provides Celgene with enforceable exclusivity over the claimed combination therapy methods through the patent term.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Combination therapy for the treatment of cancer
Grant US12605372B2 Kind: B2 Apr 21, 2026
Assignee
Celgene Corporation
Inventors
Michael D. Amatangelo, Chad Bjorklund, Anjan Thakurta, Xiankang Hong, Mariana Cota
Abstract
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab. Additionally, provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab and dexamethasone.
CPC Classifications
A61K 31/4035 A61K 31/45 A61K 47/6849 A61P 35/00
Filing Date
2022-11-09
Application No.
17983762
Claims
19
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.